TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The study was designed to evaluate the efficacy and safety of TX-12-004-HR 10 μg in treating
moderate to severe symptoms of vaginal atrophy associated with menopause after 14 days of
treatment, and to estimate the effect size and variability of vulvovaginal atrophy endpoints.
In addition, the systemic exposure to estradiol from single and multiple doses of
TX-12-004-HR was to be investigated.